Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

162 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-08

Study Completion Date

2018-07-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, randomized, blinded, parallel-group, non-inferiority, phase II/III study of the safety and effectiveness of simulated post-exposure prophylaxis with BPL HRIG with co-administration of active rabies vaccine in healthy subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

NCT02040090

Rabies

COMPLETED PHASE2/PHASE3

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

NCT00656097

Rabies

COMPLETED PHASE2

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

NCT01228383

Rabies

COMPLETED PHASE2

Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.

NCT02559921

Rabies

COMPLETED PHASE2

Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis

NCT02374814

Rabies

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each subject will undergo a total of 9 visits. Subjects' eligibility will be assessed at Screening, which can occur up to 28 days prior to dosing. Following a repeat eligibility check at Day 0, eligible subjects will be randomized and dosed with the randomized treatment (BPL HRIG + vaccine or Comparator HRIG + vaccine) on Day 0. Further assessments will be conducted on Days 3, 5, 7, 14, 28, 49 and the end of study assessment on Day 140. Vaccine will be administered on Day 0, 3, 7, 14 and 28.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Treatment A: BPL HRIG + active rabies vaccine Treatment B: Comparator HRIG + active rabies vaccine

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Double-blind study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BPL HRIG + RabAvert

20 IU/kg dose HRIG + active rabies vaccine

Group Type EXPERIMENTAL

HRIG

Intervention Type DRUG

A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.

RabAvert

Intervention Type BIOLOGICAL

A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.

Comparator HyperRab + RabAvert

20 IU/kg dose HRIG + active rabies vaccine

Group Type ACTIVE_COMPARATOR

HyperRAB

Intervention Type DRUG

A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.

RabAvert

Intervention Type BIOLOGICAL

A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HRIG

A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.

Intervention Type DRUG

HyperRAB

A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.

Intervention Type DRUG

RabAvert

A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HRIG active rabies vaccine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able and willing to sign an informed consent form.
2. Healthy male or female subjects aged 18 - 75 years inclusive.
3. No previous exposure to rabies virus, rabies vaccine and/or rabies immunoglobulin.
4. No significant abnormalities in hematology, biochemistry, or urinalysis according to the Principal Investigator's judgment.
5. No significant abnormalities in ECG according to the Investigator's judgment.
6. Females of child-bearing potential (defined from the onset of menstruation to one-year post- menopause and not surgically sterilized) who are (or become) sexually active must agree to practice contraception by using a highly effective (\>98%) method for the duration of the study.
7. Females of child-bearing potential (defined from the onset of menstruation to one-year post- menopause and not surgically sterilized) must have a negative result on a serum at screening visit and a urine HCG-based pregnancy test at Day 0.

Exclusion Criteria

1. Female subjects who are pregnant and/or lactating.
2. History of live virus vaccination, e.g., measles, mumps, varicella or rubella vaccine, within the last 3 months.
3. Planned live virus vaccination, e.g., measles, mumps, varicella or rubella vaccine, within the 3 months after Day 0.
4. History of anaphylactic or anaphylactoid hypersensitivity reactions to chicken egg; history of mild allergic reactions to chicken egg, e.g., skin rash only, is not an exclusion criterion
5. History of hypersensitivity reaction to any of the following components of active rabies vaccine (US-FDA approved) e.g.: neomycin, bovine gelatin, trace amounts of chicken protein, chlortetracycline, and amphotericin B and in accordance with the product insert of the vaccine.
6. History of life-threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products.
7. History of life-threatening allergy to blood or blood products.
8. Fever at the time of the start of the injection (oral temperature \>38ºC.) or acute illness at the time of the start of the injection. Subjects with fever on Day 0 may have entry to the study re-scheduled.
9. History of or ongoing bleeding disorder.
10. Previous organ transplant recipient.
11. Ongoing immunosuppressive illness.
12. Clinically significant illnesses including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study.
13. All types of malignancies except for basal and squamous cell (scaly or plate-like) skin cancer, in- situ cervical carcinoma must be in remission for a minimum of 5 years prior to Day 0. For non-melanoma skin cancers and carcinoma in-situ of the cervix may be enrolled if treated and cured at the time of screening.
14. Evidence of active systemic infection that requires treatment with antibiotics within 2 weeks prior to Day 0.
15. Currently receiving or have received within the past 6 months (prior to Day 0):

* immunosuppressive drugs
* immunomodulatory drugs
16. Currently receiving or have received oral or IV steroids within 14 days (prior to DAY 0) or expected to require oral or IV steroids during the study.
17. Evidence of uncontrolled hypertension (systolic blood pressure of \>150 mmHg, and/or diastolic blood pressure of \>100 mmHg).
18. Heart rate \>120/min.
19. Weight \> 95.5 kg
20. History of IgA deficiency.
21. Is positive for any of the following at screening: serological test for HIV 1\&2, HCV or HBsAg.
22. Presence of psychiatric disorder, other mental disorder or any other medical disorder which might impair the subject's ability to give informed consent or to comply with the requirements of the study protocol.
23. Previous enrollment in this study.
24. Participation in an interventional clinical trial within 30 days prior to baseline visit (Day 0).
25. Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs in the past 2 years.
26. Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes